Medical Conservation Devices (MCD)
 FWT partnered with the Dr. Bradley Fuhrman, Director of Intensive Care at Women and Children's Hospital in Buffalo, and co-inventor Mark Dowhy, to commercialize a series of proprietary and patented respiratory therapy medical devices. Given Dr. Fuhrman's focus on saving the lives of his patients each day, he effectively had no ability to pursue grant funding for his research or adequately manage a start-up company.
FWT provided the initial management team, validated the market opportunity, recruited leading clinical advisors and funded the initial prototype development. This culminated in the formation of a new company - Medical Conservation Devices, LLC - which was able to obtain additional funding from the National Institutes of Health and outside investors.
FWT has also provided a complete engineering and FDA regulatory experience with the expectation of filing the company's first 510(k) application in late 2011.
This invention is a disposable medical device, which makes delivery of inhaled anesthetics practical for the first time for infectious patients and those with severe lung injury.
Thereafter, the company will extend this initial technology to provide significant patient and treatment benefits are associated with delivering therapeutic and sedative medications to improve standard of care for pediatrics, ICU, and hard-to-sedate patients.
An estimated addressable market of $1.2 billion exists in these applications alone. Additionally, these devices can be multiplexed allowing up to 8 patients to be ventilated off of a single respirator. The value proposition to hospitals facing limited ventilation and anesthesia resource is clear and compelling. Endorsement from numerous thought leaders has further validated the opportunity.
|
